Skip to main content

EA2174 A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

NCT03604991

A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

Associated Conditions

Esophageal Cancer

Principal Investigator

Mohamedtaki Tejani

Sponsor

Eastern Cooperative Oncology Group

This study is being done to answer the following questions: (1) What are the good and bad effects of using usual chemotherapy and radiation plus the immunotherapy, nivolumab, before standard surgery for your condition?; (2) What are the good and bad effects of adding the immunotherapy nivolumab ersus adding nivolumab and ipimumab after standard surgery for your condition?; We are doing this study because we want to find out if these approaches are better or worse than the usual approach for your locoregional esophageal or gastroesophageal junction adenocarcinoma. The usual approach is defined as care most people get for locoregional esophageal or gastroesophageal junction adenocarcinoma.

This study is currently enrolling.